Heriberto Sierra
Psychiatric/Mental Health · Greenville, NCNPI 1245900646
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,083 of the $7,283 with a category attached, or 83.5%. It is spread thinly across 18 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,675 and has fallen 91.1% since, to $326 in 2024. Among psychiatric/mental health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Janssen Scientific Affairs, LLC$1K
- Sunovion Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$830
- AbbVie$627
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,12515%
- Food & beverage$6,08384%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 42 | $1,183 |
| Janssen Scientific Affairs, LLC | 1 | $1,125 |
| Sunovion Pharmaceuticals Inc. | 56 | $1,119 |
| Alkermes, Inc. | 52 | $1,051 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $830 |
| AbbVie | 21 | $627 |
| Johnson & Johnson | 13 | $490 |
| Corium, LLC | 7 | $206 |
| Otsuka America Pharmaceutical, Inc. | 8 | $178 |
| Neurocrine Biosciences, Inc. | 7 | $117 |
| Supernus Pharmaceuticals, Inc. | 3 | $94 |
| Bausch Health US, LLC | 3 | $82 |
| Lundbeck LLC | 4 | $74 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$1,265
- INVEGA$1,125
- INVEGA TRINZA$1,125
- ARISTADA$870
- AUSTEDO$599
- LYBALVI$424
- VRAYLAR$223
- ARISTADA INITIO$218
- CAPLYTA$128
- UZEDY$122
- SPRAVATO$101
How this compares
$7,283 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 22 | $141,525 |
| Invega SustennaPaliperidone Palmitate | 36 | $97,635 |
| AristadaAripiprazole Lauroxil | 12 | $37,732 |
| VraylarCariprazine Hcl | 23 | $31,829 |
| RexultiBrexpiprazole | 18 | $26,708 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $10,640 |
| Lurasidone Hcl | 36 | $5,299 |
| Clozapine | 41 | $3,185 |
| Buprenorphine Hcl | 25 | $2,871 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $2,547 |
| Fluphenazine Hcl | 32 | $2,380 |
| Aripiprazole | 57 | $1,483 |
| Bupropion XlBupropion Hcl | 26 | $1,258 |
| Duloxetine Hcl | 36 | $1,222 |
| Hydroxyzine Hcl | 45 | $1,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,183 | $141,52522 claims |
| Johnson & JohnsonInvega Sustenna | $490 | $97,63536 claims |
| Alkermes, Inc.Aristada | $1,051 | $37,73212 claims |
| AbbVieVraylar | $627 | $31,82923 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $178 | $26,70818 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $32498 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Greenville
- Maria Teresa AlexanderGreenville$12K
- Donna RackleyGreenville$6K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
- Jessica StoneRocky Mount$63K
- Deborah GranickRaleigh$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.